Five things to know about Trump’s FDA lead pick Gottlieb March 24, 2017 By Karen Appold On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick. Opinion: More industry-stakeholders play blame game for high drug costs March 23, 2017 By Devon Herrick PhD Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs. Five pharmacy regulations health execs must keep on their radars in 2017 March 19, 2017 By Kenneth Maxik Here are five critical regulations that executives can begin to prepare for today. What more transparency at the FDA means for health executives March 19, 2017 By Tracey Walker Researchers create a set of recommendations for transparency at the agency in five principal areas. More resources needed for medication-assisted treatment March 14, 2017 By Tracey Walker Include medication-assisted treatment high on the list of clinical tools used to treat opioid addiction. ACA reform must preserve mental health pharmacy access March 12, 2017 By John Figueroa ACA repeal or replacement must focus on how to preserve mental health services and pharmacy access. Cannabinoid-based drug pipeline shows promise New treatment indications are under investigation for the use of cannabinoid-based drugs. New strategies for managing drug spend: RA, Cancer, Hep C March 04, 2017 The proliferation of specialty drugs has prompted new techniques for keeping costs in tow. Cannabinoid-based drug pipeline grows: 4 ways to prepare New treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready? Payers to pharma: Here’s what we’re missing in hep C drugs February 17, 2017 By Tracey Walker A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.